Literature DB >> 31893488

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

H H Yoon, J C Bendell, F S Braiteh, I Firdaus, P A Philip, A L Cohn, N Lewis, D M Anderson, E Arrowsmith, J D Schwartz, L Gao, Y Hsu, Y Xu, D Ferry, S R Alberts, Z A Wainberg.   

Abstract

Entities:  

Year:  2019        PMID： 31893488      PMCID： PMC8902979          DOI： 10.1093/annonc/mdz454

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

Review 1.  Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.

Authors:  Massimiliano Salati; Francesco Caputo; Alessandro Bocconi; Sara Cerri; Cinzia Baldessari; Federico Piacentini; Massimo Dominici; Fabio Gelsomino
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

2.  Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer: A protocol for systematic review and meta analysis.

Authors:  Man Ju; Honggang Cheng; Kai Qu; Xiangqian Lu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.